Skip to main content
TipRanks
Go Ultimate75% OFF

Cardiol Therapeutics (CRDL) AI Stock Analysis

645 Followers
CRDL

Cardiol Therapeutics

(NASDAQ:CRDL)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Minimal financial leverageMinimal debt reduces solvency pressure and interest-related cash demands, giving Cardiol greater flexibility while it advances clinical programs. Although the company remains loss-making, its capital structure is not heavily burdened by borrowing, which can support resilience through development milestones.
Negative Factors
No demonstrated commercial revenueThe absence of meaningful revenue leaves Cardiol without operating support from product sales and makes financial performance dependent on successful clinical progress. Until a candidate is approved and commercialized, the company has limited evidence of a self-sustaining business model.

Cardiol Therapeutics (CRDL) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%CRDL-16.31%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$104.08M
Dividend Yield
―
Average Volume (3M)
1.20M
Price to Earnings (P/E)
-3.7
Beta (1Y)
1.36
Revenue Growth
―
EPS Growth
19.01%
Country
US
Employees
18
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Cardiol Therapeutics Business Overview & Revenue Model

Company Description

Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship pr...

Cardiol Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CRDL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:CPHTSE:CPH76OutperformCAD 332.68M6.7425.48%―-1.87%100.05%
TSE:GUDTSE:GUD74OutperformCAD 1.11B71.822.03%―36.15%―
TSE:MDPTSE:MDP63NeutralCAD 179.44M-96.96-2.49%―2.62%-337.50%
TSE:BHCTSE:BHC61NeutralCAD 4.60B-3.6258.90%―10.07%-328.97%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:MPHTSE:MPH49NeutralCAD 38.61M-5.40-62.34%―21.43%-115.16%

* Healthcare Sector Average

Performance Comparison

0%100%200%CRDLTSE:BHCTSE:GUDTSE:CPHTSE:MPHTSE:MDPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CRDL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CRDLCardiol Therapeutics Inc.0.86-0.16-15.49%
TSE:BHCBausch Health Companies11.813.2137.33%
TSE:GUDKnight Therapeutics11.145.1184.74%
TSE:CPHCipher Pharmaceuticals Inc13.05-1.12-7.90%
TSE:MPHMedicure Inc3.832.59208.87%
TSE:MDPMedexus Pharmaceuticals5.592.88106.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.